



Medica Central Coverage Policy

Policy Name: Fecal Calprotectin Testing MP9665

Effective Date: 08/01/2025

Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica Central plans. Coverage is subject to requirements in applicable federal or state laws. Please refer to the member's plan document for other specific coverage information. If there is a difference between this general information and the member's plan document, the member's plan document will be used to determine coverage. With respect to Medicare, Medicaid, and other government programs, this policy will apply unless these programs require different coverage.

Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions may call the Provider Service Center. Please use the Quick Reference Guide on the Provider Communications page for the appropriate phone number. <https://mo-central.medica.com/Providers/SSM-employee-health-plan-for-IL-MO-OK-providers>

Medica Central coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment.

Coverage Policy

Fecal calprotectin testing is **COVERED** for use in: (1) differentiating inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) from irritable bowel syndrome in individuals with symptoms that have lasted greater than four weeks, or (2) monitoring/managing disease activity in inflammatory bowel disease.

Fecal calprotectin testing is investigative and unproven, and therefore **NOT COVERED** for all other indications. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the effects on health care outcomes.

Description

Fecal calprotectin testing is a laboratory test that measures the amount of calprotectin present in stool. Calprotectin is a 36-kDa zinc and calcium binding protein derived from neutrophils and released by immune system cells that is thought to trigger and maintain inflammation. Therefore, it has been proposed as a noninvasive method to differentiate between inflammatory and noninflammatory gastrointestinal conditions (e.g., irritable bowel disease [IBD], irritable bowel syndrome [IBS], Crohn disease), monitor response to therapy, and predict disease recurrence. Fecal calprotectin is also under investigation as a marker in colorectal cancer, transplant rejection, and a number of other gastrointestinal conditions.

FDA Approval

Use of fecal calprotectin to differentiate IBD from IBS and for monitoring disease, including Crohn disease, is considered a procedure and is, therefore, not subject to FDA regulation. However, any medical devices, drugs, biologics, or tests used as a part of this procedure may be subject to FDA regulation. Fecal calprotectin test systems are regulated as FDA class II devices. Multiple fecal calprotectin test devices have been granted FDA clearance.



Medica Central Coverage Policy

Prior Authorization

Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.

Coding Considerations

Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Codes

83993 – Calprotectin, fecal

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division	August 16, 2023
Revised:	Medical Policy Committee/Health Services Division	August 21, 2024
Reviewed:	Medical Policy Committee/Health Services Division	August 21, 2024

Original Effective Date: 12/01/2023

Re-Review Date(s): 03/20/2025

Administrative Update: 12/27/2024 – Update to coverage policy references

© 2025 Medica.